Role of DNA methyltransferase 1 in hormone-resistant prostate cancer

Miao Fen Chen, Wen Cheng Chen, Yu Jia Chang, Ching Fang Wu, Chun Te Wu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor behavior of HR and develop more rational anti-tumor therapies. Three HR prostate cancer cell lines (androgen receptor (AR)-positive LNCaP-HR and 22RV1-HR and AR-negative PC-3) were used. Changes in tumor behavior, treatment response, and related signaling in HR were investigated in vitro and in vivo. The results revealed that constitutional activation of STAT3 and overexpressions of DNMT1 were important in the transition of HR prostate cancer. Furthermore, DNMT1 expression was required for the maintenance of STAT3 activation. When DNMT1 activity in HR was blocked, aggressive tumor behavior and treatment resistance could be overcome, which was seen in both in vitro and in vivo experiments. The underlying changes associated with inhibited DNMT1 included less epithelial-mesenchymal changes, less invasion ability, slower tumor growth, and impaired DNA repair ability, which are independent of AR and p53 status. In conclusion, altered DNMT1 expression associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide evidence for therapeutically targeting DNMT1 in HR prostate cancer.

Original languageEnglish
Pages (from-to)953-962
Number of pages10
JournalJournal of Molecular Medicine
Volume88
Issue number9
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Methyltransferases
Prostatic Neoplasms
Hormones
DNA
Androgen Receptors
Neoplasms
Therapeutics
Radiation Tolerance
Growth
DNA Repair
Prostate
Maintenance
Cell Line

Keywords

  • DNMT1
  • Hormone-resistant prostate cancer
  • Radiation
  • STAT3

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. / Chen, Miao Fen; Chen, Wen Cheng; Chang, Yu Jia; Wu, Ching Fang; Wu, Chun Te.

In: Journal of Molecular Medicine, Vol. 88, No. 9, 09.2010, p. 953-962.

Research output: Contribution to journalArticle

Chen, Miao Fen ; Chen, Wen Cheng ; Chang, Yu Jia ; Wu, Ching Fang ; Wu, Chun Te. / Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. In: Journal of Molecular Medicine. 2010 ; Vol. 88, No. 9. pp. 953-962.
@article{255da52dbf4d4910b1654fe29ac8c825,
title = "Role of DNA methyltransferase 1 in hormone-resistant prostate cancer",
abstract = "Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor behavior of HR and develop more rational anti-tumor therapies. Three HR prostate cancer cell lines (androgen receptor (AR)-positive LNCaP-HR and 22RV1-HR and AR-negative PC-3) were used. Changes in tumor behavior, treatment response, and related signaling in HR were investigated in vitro and in vivo. The results revealed that constitutional activation of STAT3 and overexpressions of DNMT1 were important in the transition of HR prostate cancer. Furthermore, DNMT1 expression was required for the maintenance of STAT3 activation. When DNMT1 activity in HR was blocked, aggressive tumor behavior and treatment resistance could be overcome, which was seen in both in vitro and in vivo experiments. The underlying changes associated with inhibited DNMT1 included less epithelial-mesenchymal changes, less invasion ability, slower tumor growth, and impaired DNA repair ability, which are independent of AR and p53 status. In conclusion, altered DNMT1 expression associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide evidence for therapeutically targeting DNMT1 in HR prostate cancer.",
keywords = "DNMT1, Hormone-resistant prostate cancer, Radiation, STAT3",
author = "Chen, {Miao Fen} and Chen, {Wen Cheng} and Chang, {Yu Jia} and Wu, {Ching Fang} and Wu, {Chun Te}",
year = "2010",
month = "9",
doi = "10.1007/s00109-010-0640-3",
language = "English",
volume = "88",
pages = "953--962",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Role of DNA methyltransferase 1 in hormone-resistant prostate cancer

AU - Chen, Miao Fen

AU - Chen, Wen Cheng

AU - Chang, Yu Jia

AU - Wu, Ching Fang

AU - Wu, Chun Te

PY - 2010/9

Y1 - 2010/9

N2 - Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor behavior of HR and develop more rational anti-tumor therapies. Three HR prostate cancer cell lines (androgen receptor (AR)-positive LNCaP-HR and 22RV1-HR and AR-negative PC-3) were used. Changes in tumor behavior, treatment response, and related signaling in HR were investigated in vitro and in vivo. The results revealed that constitutional activation of STAT3 and overexpressions of DNMT1 were important in the transition of HR prostate cancer. Furthermore, DNMT1 expression was required for the maintenance of STAT3 activation. When DNMT1 activity in HR was blocked, aggressive tumor behavior and treatment resistance could be overcome, which was seen in both in vitro and in vivo experiments. The underlying changes associated with inhibited DNMT1 included less epithelial-mesenchymal changes, less invasion ability, slower tumor growth, and impaired DNA repair ability, which are independent of AR and p53 status. In conclusion, altered DNMT1 expression associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide evidence for therapeutically targeting DNMT1 in HR prostate cancer.

AB - Given the poor outcome of patients with hormone-resistant (HR) prostate cancer, new strategies are needed to improve the current therapeutic regimens and/or develop novel treatments. We therefore aimed to provide a better understanding of the molecular mechanisms involved in the aggressive tumor behavior of HR and develop more rational anti-tumor therapies. Three HR prostate cancer cell lines (androgen receptor (AR)-positive LNCaP-HR and 22RV1-HR and AR-negative PC-3) were used. Changes in tumor behavior, treatment response, and related signaling in HR were investigated in vitro and in vivo. The results revealed that constitutional activation of STAT3 and overexpressions of DNMT1 were important in the transition of HR prostate cancer. Furthermore, DNMT1 expression was required for the maintenance of STAT3 activation. When DNMT1 activity in HR was blocked, aggressive tumor behavior and treatment resistance could be overcome, which was seen in both in vitro and in vivo experiments. The underlying changes associated with inhibited DNMT1 included less epithelial-mesenchymal changes, less invasion ability, slower tumor growth, and impaired DNA repair ability, which are independent of AR and p53 status. In conclusion, altered DNMT1 expression associated with activated STAT3 may be crucial in the transition of HR. Targeting DNMT1 could be a promising strategy for the treatment of HR prostate, as evidenced by inhibited tumor growth and enhanced radiosensitivity. These findings provide evidence for therapeutically targeting DNMT1 in HR prostate cancer.

KW - DNMT1

KW - Hormone-resistant prostate cancer

KW - Radiation

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=77956410126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956410126&partnerID=8YFLogxK

U2 - 10.1007/s00109-010-0640-3

DO - 10.1007/s00109-010-0640-3

M3 - Article

C2 - 20544341

AN - SCOPUS:77956410126

VL - 88

SP - 953

EP - 962

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 9

ER -